1-800-887-8100
COPAXONE® (glatiramer acetate injection) 40 mg/mL Logo
DOWNLOAD PRESCRIPTION & SERVICE REQUEST FORM (PSR)
MENU
Shared Solutions®
DOWNLOAD PRESCRIPTION & SERVICE REQUEST FORM (PSR)
Copaxone® is the #1 prescribed brand for relapsing MS in the US 1*

For patients with relapsing multiple sclerosis (RMS)

PAST. PRESENT. FUTURE.

An immunomodulator with demonstrated efficacy, safety, and tolerability.1

Teva is your partner in the care of relapsing MS.

Teva's COPAXONE®

As you consider your treatment goals for your relapsing MS patients— now and in years to come—you can count on Teva and COPAXONE®.

Two people taking a walk

Trusted support

Teva's Shared Solutions® can take care of many important behind-the-scenes details so you can focus on treating your patients.

VIEW SUPPORT SERVICES

Financial support

Teva is committed to helping your patients find financial solutions to start and stay on COPAXONE® treatment. Teva's Shared Solutions® offers a range of services to help COPAXONE® 40 mg/mL patients gain access to therapy. A $0 monthly co-pay is available for eligible patients.*

COPAXONE CO-PAY SOLUTIONS®

CNE and Field Nursing

Call on Shared Solutions® and Teva Field Nursing to be your partners for patient training, education, and support for Teva products. Our nationwide team is dedicated to supporting COPAXONE® patient compliance and care.

NURSING SUPPORT
Two people enjoying the sunset

COPAXONE® Tolerability

In a 3-times-a-week COPAXONE® 40 mg/mL clinical trial,1 91% of patients treated with COPAXONE® 40 mg/mL stayed on therapy for over 12 months. Approximately 3% of patients treated with COPAXONE® 40 mg/mL discontinued treatment due to an adverse event.

91%
of patients who stayed on therapy for over 12 months

The leading therapy for RMS

COPAXONE® is the #1 prescribed brand in the US since 2008.8†‡

Based on IQVIA Health National Prescription Audit, June 2018. Data proprietary to IQVIA.

The COPAXONE® brand represents 40 mg/mL and 20 mg/mL combined prescriptions.

A photo showing how COPAXONE® is thought to work

The COPAXONE® mechanism of action

An immunoactive mixture of synthesized polypeptides, COPAXONE® is thought to work by modifying immune processes that are believed to be responsible for the pathogenesis of RMS. The mechanism(s) by which COPAXONE® exerts its effect in patients with RMS are not fully understood. COPAXONE® can modify immune functions, and concerns exist about its potential to alter naturally-occurring immune responses. There is no evidence that COPAXONE® does this, but this has not been systematically evaluated.1,2,3

SEE DETAILS

3-times-a-week dosing1

Our history of innovation continued with the approval of
3-times-a-week COPAXONE® 40 mg/mL in 2014, giving relapsing MS patients the option of 208 fewer injections per year compared with daily COPAXONE® 20 mg/mL. Today, COPAXONE® remains the #1 RMS brand in the US.1

WHAT IS COPAXONE®?

COPAXONE® is an immunoactive mixture of synthesized polypeptides consisting of four naturally occurring amino acids.

Rigorously tested clinical profile

Teva rigorously tested COPAXONE® in 5 clinical trials between 1987 and 2013, demonstrating it to be an effective, safe, and tolerable choice for relapsing MS treatment.

VIEW TRIALS

3-times-a-week COPAXONE®  40 mg/mL significantly reduced relapses at 1 year1,7

Annualized relapse rate (ARR)1,7

0.505
0.331
34%
P<0.0001

Pioneering support for the relapsing MS community

The first-of-its-kind support program for the MS community, Teva's Shared Solutions® began in 1997. The program has evolved over the years to include personalized and innovative services and tools for Teva's COPAXONE® patients and healthcare practices.

SEE PROGRAM OFFERINGS

A history of scientific innovation

In the 1960s, Drs. Michael Sela and Ruth Arnon of the Weizmann Institute of Science in Rehovot, Israel, discovered copolymer 1 (now known as COPAXONE®).4 They went on to study its effectiveness in suppressing MS-like disease in animal models. The development of COPAXONE® continued through the 1970s and 1990s,4-6 and it was approved for RRMS in 1996.1

What’s next

Our commitment to research, advancements in care, and enhanced support continues for you and your relapsing MS patients.

References

  1. COPAXONE® (glatiramer acetate injection) Current Prescribing Information. Teva Neuroscience, Inc.
  2. Schellekens H, Klinger E, Muhlebach S, et al. Regul Toxicol Pharmacol. 2011;59(1):176-183.
  3. Johnson KP. Expert Opin Drug Metab Toxicol. 2010;6(5):643-660.
  4. Johnson KP. The Remarkable Story of COPAXONE. New York, NY: Diamedica Publishing; 2010.
  5. Bornstein M, Miller A, Slagle S, et al. N Engl J Med. 1987;317(7):408-414.
  6. Johnson KP, Brooks BR, Cohen JA, et al. Neurology. 1995;45(7):1268-1276.
  7. Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R; for the GALA Study Group. Ann Neurol. 2013;73(6):705-713.
  8. IQVIA Health National Prescription Audit, June 2018. Data proprietary to IQVIA.

Injections for 3-times-a-week COPAXONE® 40 mg must be at least 48 hours apart.

IMPORTANT SAFETY INFORMATION

COPAXONE® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.
Approximately 16% of patients exposed to COPAXONE® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of

You are now leaving this website

The website you are about to visit does not belong to Teva Neuroscience, Inc. or follow the same terms of service. Some of these websites may also require a third-party account, subscription, or payment to view.

While we carefully choose which websites we link to, we cannot control any changes or actions made by them. As a result, Teva makes no warranties or representations of any kind as to the accuracy, currency, or completeness of the following site, nor any liability on their behalf.

Continue to site
×